769 A single dose of intratumoral TransCon™ TLR7/8 agonist monotherapy promoted sustained activation of antigen presenting cells resulting in CD4+ and CD8+ T cell activation and tumor growth inhibition

• Amer Mirza,
• David Rosen,
• Juha Punnonen,
• Enping Hong,
• Luis Zuniga,
• Karan Uppal,
• Kathy Bang,
• Simran Sabharwal,
• Yuchi Lee,
• Solomon Martinez

Affiliations

Amer Mirza

Aff2 grid.420220.60000000403756591Xoma Corp Berkeley CA USA

David Rosen

Aff1 grid.429615.dNodality, Inc. South San Francisco CA USA

Juha Punnonen

Discovery Oncology, Merck & Co. Inc, South San Francisco, California, USA

Enping Hong

Rubius Therapeutics, Cambridge, MA, USA

Luis Zuniga

Ascendis Pharma, Redwood City, CA, USA

Karan Uppal

Ascendis Pharma, Redwood City, CA, USA

Kathy Bang

Ascendis Pharma, Redwood City, CA, USA

Simran Sabharwal

Ascendis Pharma, Redwood City, CA, USA

Yuchi Lee

Ascendis Pharma, Redwood City, CA, USA

Solomon Martinez

Ascendis Pharma, Inc., Redwood City, CA, United States